JPWO2020006312A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020006312A5 JPWO2020006312A5 JP2020571522A JP2020571522A JPWO2020006312A5 JP WO2020006312 A5 JPWO2020006312 A5 JP WO2020006312A5 JP 2020571522 A JP2020571522 A JP 2020571522A JP 2020571522 A JP2020571522 A JP 2020571522A JP WO2020006312 A5 JPWO2020006312 A5 JP WO2020006312A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- antigen
- pharmaceutical composition
- bifunctional compound
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims 37
- 102000036639 antigens Human genes 0.000 claims 37
- 108091007433 antigens Proteins 0.000 claims 37
- 230000001588 bifunctional effect Effects 0.000 claims 33
- 150000001875 compounds Chemical class 0.000 claims 33
- 230000008685 targeting Effects 0.000 claims 30
- 206010028980 Neoplasm Diseases 0.000 claims 24
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 108010008038 Synthetic Vaccines Proteins 0.000 claims 17
- 208000003174 Brain Neoplasms Diseases 0.000 claims 13
- 201000011510 cancer Diseases 0.000 claims 8
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 7
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 6
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 5
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 5
- 101001005269 Arabidopsis thaliana Ceramide synthase 1 LOH3 Proteins 0.000 claims 5
- 101001005312 Arabidopsis thaliana Ceramide synthase LOH1 Proteins 0.000 claims 5
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 5
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 5
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 5
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 5
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 5
- 101150013553 CD40 gene Proteins 0.000 claims 5
- 102100025221 CD70 antigen Human genes 0.000 claims 5
- 102100028801 Calsyntenin-1 Human genes 0.000 claims 5
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims 5
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 5
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 5
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 5
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 5
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 5
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims 5
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 5
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims 5
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims 5
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 5
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 5
- 101000668858 Spinacia oleracea 30S ribosomal protein S1, chloroplastic Proteins 0.000 claims 5
- 101000898746 Streptomyces clavuligerus Clavaminate synthase 1 Proteins 0.000 claims 5
- 102100035721 Syndecan-1 Human genes 0.000 claims 5
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 5
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 125000006239 protecting group Chemical group 0.000 claims 5
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 claims 4
- 108010055196 EphA2 Receptor Proteins 0.000 claims 4
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims 4
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims 4
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims 4
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims 4
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims 4
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 claims 4
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 claims 4
- 102100040120 Prominin-1 Human genes 0.000 claims 4
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 208000005017 glioblastoma Diseases 0.000 claims 3
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- ASDLSKCKYGVMAI-UHFFFAOYSA-N 9,10-dioxoanthracene-2-carboxylic acid Chemical compound C1=CC=C2C(=O)C3=CC(C(=O)O)=CC=C3C(=O)C2=C1 ASDLSKCKYGVMAI-UHFFFAOYSA-N 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 206010018852 Haematoma Diseases 0.000 claims 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- -1 6-methylpyrazine-2-yl Chemical group 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- 125000005620 boronic acid group Chemical group 0.000 claims 1
- 208000028919 diffuse intrinsic pontine glioma Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical group O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims 1
- 229930182470 glycoside Natural products 0.000 claims 1
- 150000002338 glycosides Chemical class 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000000527 lymphocytic effect Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025015837A JP2025072462A (ja) | 2018-06-28 | 2025-02-03 | 固形および液体悪性病変における多重ｃａｒ ｔ細胞での複数抗原の標的化 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862691486P | 2018-06-28 | 2018-06-28 | |
| US62/691,486 | 2018-06-28 | ||
| US201862697526P | 2018-07-13 | 2018-07-13 | |
| US62/697,526 | 2018-07-13 | ||
| PCT/US2019/039620 WO2020006312A1 (en) | 2018-06-28 | 2019-06-27 | Targeting of multiple antigens with multiplex car t cells in solid and liquid malignancies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025015837A Division JP2025072462A (ja) | 2018-06-28 | 2025-02-03 | 固形および液体悪性病変における多重ｃａｒ ｔ細胞での複数抗原の標的化 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021530444A JP2021530444A (ja) | 2021-11-11 |
| JP2021530444A5 JP2021530444A5 (https=) | 2022-07-04 |
| JPWO2020006312A5 true JPWO2020006312A5 (https=) | 2022-07-04 |
Family
ID=68987577
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020571522A Pending JP2021530444A (ja) | 2018-06-28 | 2019-06-27 | 固形および液体悪性病変における多重ｃａｒ ｔ細胞での複数抗原の標的化 |
| JP2025015837A Pending JP2025072462A (ja) | 2018-06-28 | 2025-02-03 | 固形および液体悪性病変における多重ｃａｒ ｔ細胞での複数抗原の標的化 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025015837A Pending JP2025072462A (ja) | 2018-06-28 | 2025-02-03 | 固形および液体悪性病変における多重ｃａｒ ｔ細胞での複数抗原の標的化 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12466869B2 (https=) |
| EP (1) | EP3813863A4 (https=) |
| JP (2) | JP2021530444A (https=) |
| CN (1) | CN112399852A (https=) |
| AU (1) | AU2019291882A1 (https=) |
| WO (1) | WO2020006312A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020366257B2 (en) | 2019-10-15 | 2025-01-23 | Diverse Biotech, Inc. | Conjugate molecules |
| WO2021102142A1 (en) * | 2019-11-19 | 2021-05-27 | Oklahoma Medical Research Foundation | Okn-007 as a therapeutic agent |
| EP4240772A4 (en) * | 2020-11-05 | 2025-02-26 | University of Pittsburgh - of the Commonwealth System of Higher Education | CONDITIONAL CONTROL OF UNIVERSAL CAR-T CELLS BY STIMULUS-RESPONSE ADAPTERS |
| EP4259648A4 (en) * | 2020-12-08 | 2025-03-26 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | Chimeric anti-EGFR antigen receptors |
| US11883499B2 (en) | 2022-02-01 | 2024-01-30 | Akos Biosciences, Inc. | Cannabinoid conjugate molecules |
| US11660348B1 (en) | 2022-02-01 | 2023-05-30 | Akos Biosciences, Inc. | Cannabinoid conjugate molecules |
| WO2025085511A1 (en) * | 2023-10-18 | 2025-04-24 | University Of Washington | Systems and methods for polymer-mediated activation of engineered cells |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200305980B (en) | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
| JP2010207133A (ja) | 2009-03-10 | 2010-09-24 | Sony Corp | 細胞分離方法 |
| DK3323830T3 (da) | 2010-06-19 | 2023-09-25 | Memorial Sloan Kettering Cancer Center | Anti-gd2 antibodies |
| ES2791716T3 (es) | 2010-12-14 | 2020-11-05 | Univ Maryland | Células T que expresan al receptor de antígeno quimérico antietiqueta universal y métodos para el tratamiento del cáncer |
| RS55764B1 (sr) | 2012-10-02 | 2017-07-31 | Gilead Sciences | Inhibitori histonskih demetilaza |
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| EP3057991B8 (en) | 2013-10-15 | 2019-09-04 | The Scripps Research Institute | Chimeric antigen receptor t cell switches and uses thereof |
| US10744207B2 (en) | 2014-05-02 | 2020-08-18 | Acepodia, Inc. | Biological complexes and methods for using same |
| MY167722A (en) | 2014-10-09 | 2018-09-21 | Univ Yamaguchi | Car expression vector and car-expressing t cells |
| WO2016154621A1 (en) | 2015-03-26 | 2016-09-29 | The California Institute For Biomedical Research | SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF |
| PL3988117T3 (pl) * | 2015-04-13 | 2025-03-10 | Pfizer Inc. | Przeciwciała terapeutyczne i ich zastosowania |
| WO2016168769A1 (en) * | 2015-04-15 | 2016-10-20 | The California Institute For Biomedical Research | Chimeric receptor t cell switches for her2 |
| WO2017112877A1 (en) | 2015-12-22 | 2017-06-29 | Icell Gene Therapeutics, Llc | Chimeric antigen receptors and enhancement of anti-tumor activity |
| CN105504042A (zh) | 2016-02-04 | 2016-04-20 | 北京艺妙神州医疗科技有限公司 | 检测car-t细胞的捕获探针、该细胞含量的检测方法及应用 |
| JP2019508036A (ja) * | 2016-02-16 | 2019-03-28 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 免疫療法組成物及び方法 |
| US20170274095A1 (en) | 2016-03-23 | 2017-09-28 | The Board Of Trustees Of The Leland Stanford Junior University | Enhanced regulatory t cells targeted to sites of inflammation with chimeric antigen receptors and expressing factors that enhance viability of pancreatic cells |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| CN110267982B (zh) * | 2016-10-19 | 2024-02-23 | 斯克利普斯研究所 | 具有人源化靶向部分和/或经过优化的嵌合抗原受体相互作用结构域的嵌合抗原受体效应细胞开关以及其用途 |
| CN110662839A (zh) | 2017-02-17 | 2020-01-07 | 珀杜研究基金会 | 用于细胞疗法的基于靶向性配体-有效负载的药物递送 |
| JP7178355B2 (ja) | 2017-02-28 | 2022-11-25 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための組成物および方法 |
| WO2018200713A1 (en) * | 2017-04-25 | 2018-11-01 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for targeted tumor immunotherapy |
| CN108490174B (zh) | 2018-04-18 | 2022-06-24 | 上海尚珞生物医药科技有限公司 | 检测car-t细胞的方法及其应用 |
| CN108660113A (zh) | 2018-05-21 | 2018-10-16 | 杭州启澜生物医学技术有限公司 | 一种制备改良型car-t细胞的方法 |
-
2019
- 2019-06-27 AU AU2019291882A patent/AU2019291882A1/en not_active Abandoned
- 2019-06-27 US US17/254,472 patent/US12466869B2/en active Active
- 2019-06-27 WO PCT/US2019/039620 patent/WO2020006312A1/en not_active Ceased
- 2019-06-27 CN CN201980043041.XA patent/CN112399852A/zh active Pending
- 2019-06-27 JP JP2020571522A patent/JP2021530444A/ja active Pending
- 2019-06-27 EP EP19825236.3A patent/EP3813863A4/en active Pending
-
2025
- 2025-02-03 JP JP2025015837A patent/JP2025072462A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021530444A5 (https=) | ||
| Cho et al. | Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside | |
| TWI786044B (zh) | 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法 | |
| JP2020505433A5 (https=) | ||
| JP2020535173A5 (https=) | ||
| Mohty et al. | New drugs before, during, and after hematopoietic stem cell transplantation for patients with acute myeloid leukemia | |
| EP3490553B1 (en) | Combination comprising an indolinone compound and its use in the treatment of lymphoma | |
| WO2016204193A1 (ja) | 抗がん剤 | |
| AU2018360559A1 (en) | Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2 inhibitors, BCL2/BCLxL inhibitors, and BCLxL inhibitors and methods of use | |
| JP2022508935A (ja) | がん治療における免疫モジュレーションのための組合せ | |
| JP2026503515A (ja) | 非ホジキンリンパ腫治療用医薬組成物及びその使用 | |
| JPWO2020006312A5 (https=) | ||
| US20200352932A1 (en) | Quinoline derivative for treatment of nasopharyngeal carcinoma | |
| KR102481856B1 (ko) | 일차 암 치료법 후 사용하기 위한 붕소-함유 프로테아좀 저해제 | |
| JP7479292B2 (ja) | 組み合わせ医薬として用いられるｅｚｈ１／２二重阻害剤を含有する医薬組成物 | |
| WO2020236667A1 (en) | Methods of treating cancer | |
| CN112043831A (zh) | 用于联合治疗乳腺癌的喹啉类化合物 | |
| JPWO2021263026A5 (https=) | ||
| CN110831604B (zh) | 用于肿瘤治疗或预防的药物组合物、方法及其用途 | |
| JPWO2020160527A5 (https=) | ||
| Friedrichs et al. | Combination of taxanes and anthracyclines in first-line chemotherapy of metastatic breast cancer: an interim report | |
| JP2006523664A5 (https=) | ||
| US20190343779A1 (en) | Emodin for Use in Gastrointestinal Cancer Therapy | |
| Schatz et al. | Darolutamide potentiates the antitumor efficacy of a PSMA-targeted thorium-227 conjugate (PSMA-TTC) in a hormone-independent prostate cancer model | |
| WO2024187968A1 (zh) | 用于治疗三阴性乳癌的药物组合物 |